Sleep Apnea Syndromes
Disorders characterized by multiple cessations of respirations during sleep that induce partial arousals and interfere with the maintenance of sleep. Sleep apnea syndromes are divided into central (see SLEEP APNEA, CENTRAL), obstructive (see SLEEP APNEA, OBSTRUCTIVE), and mixed central-obstructive types.
Subtype terms (2)
More specific conditions that are subtypes of Sleep Apnea Syndromes in the MeSH hierarchy.
- Sleep Apnea, Central
7 drugs (6 approved, 1 experimental)
- Sleep Apnea, Obstructive
166 drugs (121 approved, 45 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (30)
- hydrocodone
- montelukast
- propofol
- acetazolamide
- buspirone
- ketamine
- mometasone
- oxycodone
- ibuprofen
- sevoflurane
- hydroxychloroquine
- amlodipine
- valsartan
- acetaminophen
- levobupivacaine
- desflurane
- finasteride
- tramadol
- trazodone
- hydromorphone
- ertugliflozin
- zolpidem
- fentanyl
- losartan
- methadone
- oxygen
- morphine
- sodium chloride
- oxymetazoline
- remifentanil
Phase 3 trials (15)
Phase 2 trials (20)
Phase 1 trials (11)
Organizations
Organization Involved with Phase 4 Indications (54)
- Abbott
- Jazz Pharmaceuticals
- Cephalon
- Merck
- Wyeth
- GlaxoSmithKline
- Sunovion
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- United States Army
- Associação Fundo de Incentivo à Pesquisa
- Shahid Beheshti University of Medical Sciences
- Aarhus University
- University of Manitoba
- Chang Gung University
- Emory University
- Federal University of Rio Grande do Sul
- Institut National de la Santé Et de la Recherche Médicale, France
- Katholieke Universiteit Leuven
- Masih Daneshvari Hospital
- McGill University
- Skaraborg Hospital
- University of Lausanne
- University of Louisville
- University of Michigan
- University of South Florida
- University of Toronto
- University of Alberta
- University of Bologna
- +24 more
Organization Involved with Phase 3 Indications (27)
- Takeda
- Novo Nordisk
- Bioprojet
- Hamilton Health Sciences Corporation
- OSR Medical Inc.
- Clayton Sleep Insititute
- University of Pennsylvania
- University of London
- Harvard University
- Duke University
- Harbin Medical University
- Ohio State University
- Romaker & Associates
- University of Medicine and Dentistry of New Jersey
- University of Saskatchewan
- Chinese University of Hong Kong
- St. Louis University
- University of Turku
- Papworth Hospital NHS Foundation Trust
- University of Limoges
- University of Montreal
- University of Alabama, Birmingham
- University of Western Ontario
- Government of France
- Fond de dotation AGIR pour les maladies chroniques
- The University of Texas, Dallas
- Apnimed, Inc.
Organization Involved with Phase 2 Indications (39)
- Actelion
- Eisai
- Roche
- Sanofi
- Vivus
- Bayer
- Merz
- Solvay
- American Academy of Otolaryngology-Head and Neck Surgery Foundation
- National Center for Research Resources (NCRR)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Maastricht University
- University of Arizona
- American Heart Association
- Istituto Auxologico Italiano
- Johns Hopkins University
- Liaoyang Central Hospital
- Monash University
- Northwell Health
- Northwestern University
- University of Southern California
- Mayo Clinic
- Centre de Recherche en Nutrition Humaine Rhone-Alpe
- Columbia University
- University of Calgary
- Mid-Atlantic Epilepsy and Sleep Center
- University of Texas at Houston
- State University of New York, Brooklyn
- University of Wisconsin
- University of Illinois at Chicago
- +9 more
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (26)
- ResMed
- Teva
- Beijing Anzhen Hospital
- Case Western Reserve University
- Advent Health
- Guangzhou Medical University
- Kyoto University
- Memorial Hermann Health System
- New York University
- Stanford University
- University of Iowa
- University of Rochester
- University of Athens
- Virginia Commonwealth University
- Yonsei University
- Capital Medical University
- Sohag University
- Tel Aviv University
- University of California, San Francisco
- Jiao Tong University
- University of Montpellier
- Hebrew University
- Health Research Board, Ireland
- ResMed Foundation
- National University of Ireland
- Shanghai Stomatological Hospital